2021
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D’Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021, 592: 450-456. PMID: 33762733, PMCID: PMC8046670, DOI: 10.1038/s41586-021-03362-0.Peer-Reviewed Original ResearchConceptsNon-alcoholic steatohepatitisNon-viral hepatocellular carcinomaAnti-PD1 treatmentT cellsHepatocellular carcinomaNASH-HCCImmune surveillanceRandomized phase III clinical trialsPhase III clinical trialsAberrant T cell activationAnti-PDL1 treatmentAnti-tumor surveillanceStudy of immunotherapyDepletion of CD8Advanced hepatocellular carcinomaTumor immune surveillanceStratification of patientsBiomarker-based stratificationT cell activationAdjuvant treatmentOverall survivalTNF neutralizationDeath-1Immune therapyTherapeutic immunotherapy
2008
Relationship between T Cell Activation and CD4+ T Cell Count in HIV-Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy
Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship between T Cell Activation and CD4+ T Cell Count in HIV-Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy. The Journal Of Infectious Diseases 2008, 197: 126-133. PMID: 18171295, PMCID: PMC3466592, DOI: 10.1086/524143.Peer-Reviewed Original ResearchConceptsUndetectable plasma HIV RNA levelsT cell activationPlasma HIV RNA levelsHIV RNA levelsHIV-negative subjectsHigh LPS levelsCell activationCell countAntiretroviral therapyLPS levelsHigh T-cell activation levelsHIV-specific immune responsesT cell activation levelsUntreated human immunodeficiency virusPlasma lipopolysaccharide levelsRNA levelsHIV-seropositive individualsT-cell countsT cell lossHuman immunodeficiency virusAbsence of therapyActivation levelsCells/Measurable viremiaMucosal translocation
2005
Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment
Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, Martin JN, Nixon DF, McCune JM, Deeks SG. Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment. Journal Of Virology 2005, 79: 14169-14178. PMID: 16254352, PMCID: PMC1280210, DOI: 10.1128/jvi.79.22.14169-14178.2005.Peer-Reviewed Original ResearchConceptsHIV-specific T cellsT cellsT cell activationHIV diseaseImmune activationHuman immunodeficiency virus (HIV) replicationAdvanced HIV diseaseDrug-resistant viremiaGeneralized immune activationHIV-specific ILMultidrug-resistant HIVQuiescent immune systemActive antiretroviral therapyCytokine flow cytometryT cell controlHigh-level viremiaLow-level viremiaPresence of HIVT cell subsetsHuman immunodeficiency virusImmunodeficiency virus replicationT cell subpopulationsAbsence of therapyPresence of therapyAntiretroviral therapy